SCA
CORT icon

SAC Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

SAC Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-14,329
Closed -$62K – 242
2014
Q1 		$62K Buy
+14,329
New +$50.1K ﹤0.01% 1699
2013
Q4 		– Sell
-500,000
Closed -$795K – 1803
2013
Q3 		$795K Buy
500,000
+50,000
+11% +$88.2K ﹤0.01% 989
2013
Q2 		$779K Buy
+450,000
New +$809K ﹤0.01% 969

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

SAC Capital Advisors's CORT Position: Q2 2014 in Review

SAC Capital Advisors sold out of Corcept Therapeutics (CORT) in Q2 2014, closing a stake of 14,329 shares — an estimated $62K sold.

SAC Capital Advisors first reported a position in CORT in Q2 2013 and held it in 3 quarters. The position peaked at $795K in Q3 2013. 62 funds tracked by Wall St. Rank hold CORT as of Q2 2014.

  • SAC Capital Advisors reported no remaining Corcept Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 14,329 Corcept Therapeutics shares in Q2 2014, an estimated $62K.
  • SAC Capital Advisors first reported a position in Corcept Therapeutics in Q2 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Corcept Therapeutics position peaked at $795K in Q3 2013.
  • 62 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.